IMMUNICONCEPT INDIA PVT. LTD. F-242A, Street No

Total Page:16

File Type:pdf, Size:1020Kb

IMMUNICONCEPT INDIA PVT. LTD. F-242A, Street No IMMUNICONCEPT INDIA PVT. LTD. F-242A, Street No. 7, Pandav Nagar, Mayur Vihar Phase-I, New Delhi-110091 Tel.: +91 11 22753711, 43063564 [email protected] Fax.: +91 11 22753710 [email protected] IMMUNICONCEPT INDIA PVT. LTD. www.immunoconceptindia.com Product Catalog-Diagnostics (Elisa Kits & Rapid Tests) INDEX STREPTAVIDIN - COATED WELLS ELISA KITS Pack Size Kit sensitivity/ Product Name Incubation Standard Range SL.NO DESCRIPTION SHEET (Wells) components specificity TSH Elisa Kit (Serum/Plasma) 60'/15' at RT 96/192/480 7 cal(0-40ng/ml),with control RTU/CE,IVD 0.037ng/ml 1 STREPTAVIDIN - COATED WELLS ELISA KITS 1 T3 Elisa Kit (Serum/Plasma) 60'/15' at RT 96/192 6 cal(0-8ng/ml),with control RTU/CE,IVD 0.037ng/ml T4 Elisa Kit (Serum/Plasma) 60'/15' at RT 96/192 6 cal(0-25µg/dl),with control RTU/CE,IVD 0.16µg/dl 2 REPRODUCTION (Fertility & Steroidal Hormone) 2 6 cal(0-100mIU/ml),with FSH Elisa Kit (Serum/Plasma) 60'/15' at RT 96 RTU/CE,IVD 0.002mIU/ml control 3 TUMER MARKER (CANCER MARKER) 4 6 cal(0-200mIU/ml),with LH Elisa Kit (Serum/Plasma) 45'/15'at RT 96 RTU/CE,IVD 0.012 mIU/ml control 4 VITAMINS DETECTION KITS 5 6 cal(0-250mIU/ml),with HCG Elisa Kit (Serum/Plasma) 60'/15'at RT 96 RTU/CE,IVD 0.082mIU/ml control Prolactin Elisa Kit (Serum/ 5 PRENATAL SCREENING 6 60'/15'at RT 96 6 cal(0-100ng/ml),with control RTU/CE,IVD 0.002 mIU/ml Plasma) 6 AUTOIMMUNITY 7 FT3 Elisa Kit (Serum/Plasma) 45'/15'at RT 96 6 cal(0-16pg/ml),with control RTU/CE,IVD 0.037pg/ml FT4 Elisa Kit (Serum/Plasma) 45'/15'at RT 96 6 cal(0-8ng/ml),with control RTU/CE,IVD 0.017ng/ml 7 DIABETES / OBESITY 8 CEA Elisa Kit (Serum/Plasma) 45'/15'at RT 96 6 cal(0-250ng/ml),with control RTU/CE,IVD 0.1 ng/ml F-PSA Elisa Kit (Serum/Plas- 60'/15'at RT 96 6 cal(0-ng/ml),with control RTU/CE,IVD 0.03ng/ml 8 ALLERGY/ ASTHMA/COPD 9 ma) tPSA Elisa Kit (Serum/Plasma) 30'/15'at RT 96 6 cal(0-100ng/ml),with control RTU/CE,IVD 0.07ng/ml CA 19.9 Elisa Kit (Serum/ 9 BONE & MINERAL METABOLISM 10 inquire 96 RTU/CE,IVD Plasma) CA 15.3 Elisa Kit(Serum/ 10 NEUROLOGY 11 inquire 96 RTU/CE,IVD Plasma) CA 125 Elisa Kit (Serum/ inquire 96 RTU/CE,IVD 11 NEPHROLOGY 12 Plasma) AFP Elisa Kit (Serum/Plasma) 45'/15'at RT 96 6 cal(0-500ng/ml),with control RTU/CE,IVD 0.67ng/ml 12 INFECTIOUS DISEASE MARKERS 13 Ferritin Elisa kit (Serum/ 30'/30'/15'at RT 96 6 cal(0-800ng/ml),with control RTU/CE,IVD 0.82ng/ml Plasma) 13 CARDIAC PANEL 14 Anti - TPO Elisa Kit (Serum/ 60'/30'/15'at RT 96 6 cal(0-500U/ml),with control RTU/CE,IVD 0.90 U/ml Plasma) Anti - TG Elisa Kit (Serum/ 14 GASTROENTEROLOGY (IBD/Crohn`s/CELIAC DISEASE/ULCERATIVE COLITIS) 15 60'/30'/15'at RT 96 6 cal(0-2000U/ml),with control RTU/CE,IVD 2.00U/ml Plasma) Total IgE Elisa Kit (Serum/ 15 COMPLEMENT 16 30'/30'/15'at RT 96 6 cal(0-400 IU/ml),with control RTU/CE,IVD 1.0 Iu/ml Plasma) HS - CRP Elisa Kit (Serum/ inquire 96 RTU/CE,IVD 16 HEPATITIS MARKERS 17 Plasma) Myoglobin Elisa Kit (Serum/ inquire 96 RTU/CE,IVD 17 FOOD SAFETY/ANALYTES/ADULTERATION TESTING 18 Plasma) cTroponin I Elisa Kit (Serum/ inquire 96 RTU/CE,IVD 18 SALIVARY ELISA KITS 19 Plasma) Vitamin B12 Elisa Kit (Serum/ 6 cal(0-2500 pg/ml),with 60'/10'-15'at RT 96 RTU/CE,IVD 75pg/ml 19 STOOL TEST ELISA KIT 20 Plasma) control Folic Acid Elisa Kit(Serum/ 60'/10'-15'at RT 96 6 cal(0-25ng/ml),with control RTU/CE,IVD 0.48ng/ml Plasma) 20 BIOGENIC AMINES 21 25 OH Vitamin D Elisa Kit 60'/10'-15'at RT 96 6 cal(0-150ng/ml),with control RTU/CE,IVD 0.40ng/ml (Serum/Plasma) 21 RAPID TESTS KITS 3 AMH Elisa Kit (Serum/Plasma) 60'/10'-15'at RT 96 6 cal(0-20ng/ml),with control RTU/CE,IVD 0.025ng/ml 01 04 REPRODUCTION TUMOR/CANCER MARKERS Pack Size Sensitivity / Pack Size sensitivity/ Product Name Incubation Standard Range Kit Compnents Product Name Incubation Standard Range kit Components (Wells) Specificity (Wells) specificity HCG (Serum/Plasma ) 60'/15' 96 6 Cal.( 0-500 IU/l ) With Control Ready to use CE-IVD 1.25 IU/l TOTAL PSA (HS) in (Serum/Plasma) 60'/15' 96 5 Cal(0-30ng/ml)with control RTU/CE, IVD 0.05ng/ml LH (Serum/Plasma ) 60'/15' 96 5 Cal. (0-100 IU/l) With Control Ready to use CE-IVD 0.15 IU/l FREE PSA in (Serum/Plasma) 30'/30'/15' 96 5 Cal(0-5ng/ml)with control RTU/CE, IVD 0.035ng/ml FSH (Serum/Plasma ) 60'/15' 96 5 Cal. (0-100 IU/l) With Control Ready to use CE-IVD 0.15 IU/l CA 12-5 in (Serum/Plasma) 60'/15' 96 6 Cal(0-400U/ml)with control RTU/CE, IVD 0.25U/ml 5 Cal. (0-2000 mIU/l) With PRL ( Serum/Plasma ) 60'/15' 96 Ready to use CE-IVD 5.0mIU/l Control CA 15-3/M12 in (Serum/Plasma) 30'/30'/15' 96 5 Cal(0-250U/ml)with control RTU/CE, IVD 0.75U/ml ESTRADIOL (Serum/Plasma ) 120'/15' 96 6 Cal.(0-20 nmol/l ) With Control Ready to use CE-IVD 0.025 nmol/l CA 19-9 in (Serum/Plasma) 30'/30'/15' 96 5 Cal(0-240U/ml)with control RTU/CE, IVD 1.0U/ml 7 Cal. (0-300 nmol/l) With PROGESTERONE (Serum/Plasma) 120'/15' 96 Ready to use CE-IVD 0.25 nmol/l CA 72-4 in (Serum/Plasma) 120'/60'/15 96 5 Cal(0-200U/ml)with control RTU/CE, IVD 1.0U/ml Control CYFRA 21-1 60'/15' 96 5 Cal(0-50ng/ml)with control RTU/CE, IVD 0.5ng/ml 17(OH) PROGESTERONE (Serum/ 6 Cal. (0-10 ng/ml) With 60'/15' 96 Ready to use CE-IVD 0.09 ng/mL Plasma ) Control CA 27-29/M20 60'/15' 96 6 Cal(0-50U/ml)with control RTU/CE, IVD 0.5U/ml 6 Cal. (0-100 nmol/l) With TESTOSTERONE (Serum/Plasma) 120'/15' 96 Ready to use CE-IVD 0.15 nmol/l Control M22 30'/30'/15' 96 6 Cal(0-100U/ml)with control RTU/CE, IVD 0.75U/ml FREE-TESTOSTERONE (Serum/Plas- 6 Cal. (0-100 pg/ml) With 60'/15' 96 Ready to use CE-IVD 0.06 pg/mL CEA 60'/15' 96 6 Cal(0-64ng/ml)with control RTU/CE, IVD 0.50ng/ml ma ) Control AFP 60'/15' 96 6 Cal(0-500U/ml)with control RTU/CE, IVD 0.50U/ml DHT (Serum/Plasma ) Inquire 5 Cal. (0-277.8 nmol/L) With HCG/β-HCG With Median's val- SHBG (Serum/Plasma ) 60'/15' 96 Ready to use CE-IVD nmol/L 60'/15' 96 6 Cal(0-500IU/l)with control RTU/CE, IVD 1.25IU/l Control ue(14-21st week) 6 Cal. (0-10 ug/ml) With NSE(Neuron Specific Enolase) 30'/30'/15' 96 6 Cal(0-150µg/l)with control RTU/CE, IVD 0.3µg/l DHEA-S (Serum/Plasma ) 60'/15' 96 Ready to use CE-IVD 0.025 ug/ml Control S-100 B inquire 96 RTU/CE, IVD ACTH ( Serum/Plasma) Inquire Chromogranin A Inquire 96 RTU/CE, IVD PTH (Serum/Plasma ) Inquire HE 4 (ovarian cancer confirmatory 6 Cal(0-1000pmol/l)with 25 (OH) Vitamin D (Serum/Plasma 60'/15' 96 RTU/CE, IVD 10ppmol/l 60'/10'-15' 96 6 Cal. (0-150 pg/ml) With Control Ready to use CE-IVD 75pg/ml marker) control ) Vitamin B12 Elisa Kit (Serum/ 5 Cal. (0-2500ng/ml) With HE4 Rapid Test inquire 10test 60'/10'-15' 96 Ready to use CE-IVD 0.48ng/ml Plasma ) Control DM 1 ADC(trastuzumab Emtansine (T- Folic Acid Elisa Kit (Serum/Plasma DM1)Antibody-Drug Conjugate) competi- inquire 96 60'/10'-15' 96 5 Cal. (0-100 ng/ml) With Control Ready to use CE-IVD 0.40ng/ml ) tive OR Sandwich ELISA 6 Cal. (0-30 ng/ml) With MMAE ADC(Monomethyl auristatin E DHEA ( Serum/Plasma ) 60'/20' 96 Ready to use CE-IVD 0.10 ng/mL Control Antibody Drug Conjugate) competitive inquire 96 OR Sandwich ELISA Androstenedione (Serum/Plasma) 60'/15' 96 6 Cal. (0-10 ng/l) With Control Ready to use CE-IVD 0.01 ng/mL MMAF ADC(Monomethyl Auristatin F Aldosterone (Serum/Plasma / 6 Cal. (0-2000 pg/ml ) With 60'/20' 96 Ready to use CE-IVD 95% Antibody Drug Conjugate)Competitive Or inquire 96 Urine ) Control Sandwich ELISA Renin (Serum/Plasma ) Inquire B2 Microglobulin Elisa Kit inquire 96 5 Cal. (0-100 ng/ml ) With Cortisol ( Serum/Plasma ) 60'/15' Ready to use CE-IVD 95% Control TPA Elisa Kit inquire 96 AMH Elisa Kit ( Serum/Plasma ) 60'/15' 96 6 Cal. (0-20 ) With Control Ready to use CE-IVD Human alpha - Fetoprotein Lens Culinaris inquire 96 Agglutiin 3 Elisa Kit (Liver Cancer) HUMAN PLACENTAL LACTOGEN 30'/15' 96 5 (0-20 ,liq.stable) With Contrlo Ready to use CE-IVD 0.03 mg/l ELISA KIT( Serum/Plasma ) THYROGLOBULIN Antigen (TG) Elisa Kit 60'/15' 96 5 Cal(0-400ng/ml) with control RTU/CE, IVD 1.0 ng/ml 03 04 VITAMINS DETECTION KIT PRENATAL SCREENING Pack Pack Size kit Compo- Sensitivity / Product Name Incubation Standard Range sensitivity Product Name Incubation Size Standard Range Kit Compnents (Wells) nents Specificity (Wells) PAPP-A in (Serum/Plasma)With (9- 6 Cal (0-10000mU/l) 6 (0-150, liq.
Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • Neuroinflammation Triggered by Β-Glucan/Dectin-1 Signaling Enables CNS Axon Regeneration
    Neuroinflammation triggered by β-glucan/dectin-1 signaling enables CNS axon regeneration Katherine T. Baldwina,b,1, Kevin S. Carbajalc,d,1, Benjamin M. Segalc,d,2, and Roman J. Gigera,b,c,d,2 aDepartment of Cell and Developmental Biology, bCellular and Molecular Biology Graduate Program, cNeuroscience Graduate Program, and dHoltom-Garrett Program in Neuroimmunology, Department of Neurology, University of Michigan School of Medicine, Ann Arbor, MI 48109 Edited by Ben A. Barres, Stanford University School of Medicine, Stanford, CA, and approved January 22, 2015 (received for review December 22, 2014) Innate immunity can facilitate nervous system regeneration, yet growth can be undermined by concurrent toxicity (9). A deeper the underlying cellular and molecular mechanisms are not well understanding of these opposing effects will be important for understood. Here we show that intraocular injection of lipopoly- exploiting immunomodulatory pathways to promote neural re- saccharide (LPS), a bacterial cell wall component, or the fungal cell pair while minimizing bystander damage. wall extract zymosan both lead to rapid and comparable intravi- In the present study, we investigated the pathways that drive treal accumulation of blood-derived myeloid cells. However, when innate immune-mediated axon regeneration after ONC. We in- combined with retro-orbital optic nerve crush injury, lengthy duced sterile inflammation in the vitreous on the day of injury by growth of severed retinal ganglion cell (RGC) axons occurs only i.o. administration of zymosan or constituents of zymosan clas- in zymosan-injected mice, and not in LPS-injected mice. In mice sified as pathogen-associated molecular patterns (PAMPs). PAMPs dectin-1 deficient for the pattern recognition receptor but not are highly conserved microbial structures that serve as ligands for TLR2 , Toll-like receptor-2 ( ) zymosan-mediated RGC regeneration pattern recognition receptors (PRRs).
    [Show full text]
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • Deficiency in Class III PI3-Kinase Confers Postnatal Lethality with IBD
    ARTICLE DOI: 10.1038/s41467-018-05105-8 OPEN Deficiency in class III PI3-kinase confers postnatal lethality with IBD-like features in zebrafish Shaoyang Zhao1,2,3, Jianhong Xia2,3, Xiuhua Wu2,3, Leilei Zhang2,3, Pengtao Wang2,3, Haiyun Wang2,3, Heying Li2, Xiaoshan Wang 2, Yan Chen 2, Jean Agnetti2, Yinxiong Li 2, Duanqing Pei2,3 & Xiaodong Shu2,3 The class III PI3-kinase (PIK3C3) is an enzyme responsible for the generation of phospha- tidylinositol 3-phosphate (PI3P), a critical component of vesicular membrane. Here, we report 1234567890():,; that PIK3C3 deficiency in zebrafish results in intestinal injury and inflammation. In pik3c3 mutants, gut tube forms but fails to be maintained. Gene expression analysis reveals that barrier-function-related inflammatory bowel disease (IBD) susceptibility genes (e-cadherin, hnf4a, ttc7a) are suppressed, while inflammatory response genes are stimulated in the mutants. Histological analysis shows neutrophil infiltration into mutant intestinal epithelium and the clearance of gut microbiota. Yet, gut microorganisms appear dispensable as mutants cultured under germ-free condition have similar intestinal defects. Mechanistically, we show that PIK3C3 deficiency suppresses the formation of PI3P and disrupts the polarized dis- tribution of cell-junction proteins in intestinal epithelial cells. These results not only reveal a role of PIK3C3 in gut homeostasis, but also provide a zebrafish IBD model. 1 School of Life Sciences, University of Science and Technology of China, 230027 Hefei, Anhui, China. 2 CAS Key Laboratory of Regenerative Biology, Guangzhou Institute of Biomedicine and Health-Guangzhou Medical University Joint School of Biological Sciences, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 510530 Guangzhou, China.
    [Show full text]
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • PROTEOMIC ANALYSIS of HUMAN URINARY EXOSOMES. Patricia
    ABSTRACT Title of Document: PROTEOMIC ANALYSIS OF HUMAN URINARY EXOSOMES. Patricia Amalia Gonzales Mancilla, Ph.D., 2009 Directed By: Associate Professor Nam Sun Wang, Department of Chemical and Biomolecular Engineering Exosomes originate as the internal vesicles of multivesicular bodies (MVBs) in cells. These small vesicles (40-100 nm) have been shown to be secreted by most cell types throughout the body. In the kidney, urinary exosomes are released to the urine by fusion of the outer membrane of the MVBs with the apical plasma membrane of renal tubular epithelia. Exosomes contain apical membrane and cytosolic proteins and can be isolated using differential centrifugation. The analysis of urinary exosomes provides a non- invasive means of acquiring information about the physiological or pathophysiological state of renal cells. The overall objective of this research was to develop methods and knowledge infrastructure for urinary proteomics. We proposed to conduct a proteomic analysis of human urinary exosomes. The first objective was to profile the proteome of human urinary exosomes using liquid chromatography-tandem spectrometry (LC- MS/MS) and specialized software for identification of peptide sequences from fragmentation spectra. We unambiguously identified 1132 proteins. In addition, the phosphoproteome of human urinary exosomes was profiled using the neutral loss scanning acquisition mode of LC-MS/MS. The phosphoproteomic profiling identified 19 phosphorylation sites corresponding to 14 phosphoproteins. The second objective was to analyze urinary exosomes samples isolated from patients with genetic mutations. Polyclonal antibodies were generated to recognize epitopes on the gene products of these genetic mutations, NKCC2 and MRP4. The potential usefulness of urinary exosome analysis was demonstrated using the well-defined renal tubulopathy, Bartter syndrome type I and using the single nucleotide polymorphism in the ABCC4 gene.
    [Show full text]
  • Placental Growth Hormone-Related Proteins and Prolactin-Related Proteins
    Placental Growth Hormone-Related Proteins and Prolactin-Related Proteins The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Haig, D. 2008. Placental growth hormone-related proteins and prolactin-related proteins. Placenta 29: 36-41. Published Version doi:10.1016/j.placenta.2007.09.010 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11148777 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Placental growth hormone-related proteins and prolactin-related proteins. David Haig Department of Organismic and Evolutionary Biology, Harvard University, 26 Oxford Street, Cambridge MA 02138. e-mail: [email protected] phone: 617-496-5125 fax: 617-495-5667 Keywords: GH, PRL, placenta, endometrial glands, placental lactogen The placentas of ruminants and muroid rodents express prolactin (PRL)-related genes whereas the placentas of anthropoid primates express growth hormone (GH)-related genes. The evolution of placental expression is associated with acclerated evolution of the corresponding pituitary hormone and destabilization of conserved endocrine systems. In particular, placental hormones often evolve novel interactions with new receptors. The adaptive functions of some placental hormones may be revealed only under conditions of physiological stress. Introduction Placental hormones are produced by offspring, but act on receptors of mothers. As such, placental hormones and maternal receptors are prime candidates for the expression of parent-offspring conflict [1,2].
    [Show full text]
  • Pathophysiology of Gestational Diabetes Mellitus: the Past, the Present and the Future
    6 Pathophysiology of Gestational Diabetes Mellitus: The Past, the Present and the Future Mohammed Chyad Al-Noaemi1 and Mohammed Helmy Faris Shalayel2 1Al-Yarmouk College, Khartoum, 2National College for Medical and Technical Studies, Khartoum, Sudan 1. Introduction It is just to remember that “Pathophysiology” refers to the study of alterations in normal body function (physiology and biochemistry) which result in disease. E.g. changes in the normal thyroid hormone level causes either hyper or hypothyroidism. Changes in insulin level as a decrease in its blood level or a decrease in its action will cause hyperglycemia and finally diabetes mellitus. Scientists agreed that gestational diabetes mellitus (GDM) is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy. From our experience most women with GDM in the developing countries are not aware of the symptoms (i.e., the disease will be symptomless). While some of the women will have few symptoms and their GDM is most commonly diagnosed by routine blood examinations during pregnancy which detect inappropriate high level of glucose in their blood samples. GDM should be confirmed by doing fasting blood glucose and oral glucose tolerance test (OGTT), according to the WHO diagnostic criteria for diabetes. A decrease in insulin sensitivity (i.e. an increase in insulin resistance) is normally seen during pregnancy to spare the glucose for the fetus. This is attributed to the effects of placental hormones. In a few women the physiological changes during pregnancy result in impaired glucose tolerance which might develop diabetes mellitus (GDM). The prevalence of GDM ranges from 1% to 14% of all pregnancies depending on the population studied and the diagnostic tests used.
    [Show full text]
  • Angiopoietin/Tek Interactions Regulate MMP-9 Expression and Retinal Neovascularization
    0023-6837/03/8311-1637$03.00/0 LABORATORY INVESTIGATION Vol. 83, No. 11, p. 1637, 2003 Copyright © 2003 by The United States and Canadian Academy of Pathology, Inc. Printed in U.S.A. Angiopoietin/Tek Interactions Regulate MMP-9 Expression and Retinal Neovascularization Arup Das, William Fanslow, Douglas Cerretti, Erin Warren, Nicholas Talarico, and Paul McGuire Department of Surgery (AD, PM), Division of Ophthalmology, Cell Biology and Physiology (AD, EW, NT, PM), University of New Mexico School of Medicine, and New Mexico Veterans Health Care System (AD), Albuquerque, New Mexico; and Cancer Pharmacology Amgen Washington (WF, DC), Seattle, Washington SUMMARY: The objective of the study was to determine the role of the angiopoietins in the regulation of gelatinase expression during angiogenesis, and whether inhibition of the angiopoietin/Tek interaction in vivo can suppress the extent of retinal neovascularization. Retinal microvascular endothelial cells were treated with angiopoietins and examined for the production of gelatinases. The effects of inhibiting angiopoietin binding to the Tie-2 receptor was studied in newborn mice with experimentally induced retinal neovascularization. Animals were treated with an ip injection of the Tie-2 antagonist, muTek delta Fc, while oxygen-exposed mice treated with similar concentrations of murine IgG were used as controls. The effect of muTek delta Fc on the gelatinase expression in the retina was examined by real-time RT-PCR analysis. The stimulation of cultured retinal endothelial cells with Ang-1 and -2 resulted in the increased expression of matrix metalloproteinase (MMP)-9. Ang-2 expression was up-regulated in experimental animals during the period of angiogenesis and was the greatest on Day 17 (the time of maximal angiogenic response).
    [Show full text]
  • Appendix Table A.2.3.1 Full Table of All Chicken Proteins and Human Orthologs Pool Accession Human Human Protein Human Product Cell Angios Log2( Endo Gene Comp
    Appendix table A.2.3.1 Full table of all chicken proteins and human orthologs Pool Accession Human Human Protein Human Product Cell AngioS log2( Endo Gene comp. core FC) Specific CIKL F1NWM6 KDR NP_002244 kinase insert domain receptor (a type III receptor tyrosine M 94 4 kinase) CWT Q8AYD0 CDH5 NP_001786 cadherin 5, type 2 (vascular endothelium) M 90 8.45 specific CWT Q8AYD0 CDH5 NP_001786 cadherin 5, type 2 (vascular endothelium) M 90 8.45 specific CIKL F1P1Y9 CDH5 NP_001786 cadherin 5, type 2 (vascular endothelium) M 90 8.45 specific CIKL F1P1Y9 CDH5 NP_001786 cadherin 5, type 2 (vascular endothelium) M 90 8.45 specific CIKL F1N871 FLT4 NP_891555 fms-related tyrosine kinase 4 M 86 -1.71 CWT O73739 EDNRA NP_001948 endothelin receptor type A M 81 -8 CIKL O73739 EDNRA NP_001948 endothelin receptor type A M 81 -8 CWT Q4ADW2 PROCR NP_006395 protein C receptor, endothelial M 80 -0.36 CIKL Q4ADW2 PROCR NP_006395 protein C receptor, endothelial M 80 -0.36 CIKL F1NFQ9 TEK NP_000450 TEK tyrosine kinase, endothelial M 77 7.3 specific CWT Q9DGN6 ECE1 NP_001106819 endothelin converting enzyme 1 M 74 -0.31 CIKL Q9DGN6 ECE1 NP_001106819 endothelin converting enzyme 1 M 74 -0.31 CWT F1NIF0 CA9 NP_001207 carbonic anhydrase IX I 74 CIKL F1NIF0 CA9 NP_001207 carbonic anhydrase IX I 74 CWT E1BZU7 AOC3 NP_003725 amine oxidase, copper containing 3 (vascular adhesion protein M 70 1) CIKL E1BZU7 AOC3 NP_003725 amine oxidase, copper containing 3 (vascular adhesion protein M 70 1) CWT O93419 COL18A1 NP_569712 collagen, type XVIII, alpha 1 E 70 -2.13 CIKL O93419
    [Show full text]
  • Cloud-Clone 16-17
    Cloud-Clone - 2016-17 Catalog Description Pack Size Supplier Rupee(RS) ACB028Hu CLIA Kit for Anti-Albumin Antibody (AAA) 96T Cloud-Clone 74750 AEA044Hu ELISA Kit for Anti-Growth Hormone Antibody (Anti-GHAb) 96T Cloud-Clone 74750 AEA255Hu ELISA Kit for Anti-Apolipoprotein Antibodies (AAHA) 96T Cloud-Clone 74750 AEA417Hu ELISA Kit for Anti-Proteolipid Protein 1, Myelin Antibody (Anti-PLP1) 96T Cloud-Clone 74750 AEA421Hu ELISA Kit for Anti-Myelin Oligodendrocyte Glycoprotein Antibody (Anti- 96T Cloud-Clone 74750 MOG) AEA465Hu ELISA Kit for Anti-Sperm Antibody (AsAb) 96T Cloud-Clone 74750 AEA539Hu ELISA Kit for Anti-Myelin Basic Protein Antibody (Anti-MBP) 96T Cloud-Clone 71250 AEA546Hu ELISA Kit for Anti-IgA Antibody 96T Cloud-Clone 71250 AEA601Hu ELISA Kit for Anti-Myeloperoxidase Antibody (Anti-MPO) 96T Cloud-Clone 71250 AEA747Hu ELISA Kit for Anti-Complement 1q Antibody (Anti-C1q) 96T Cloud-Clone 74750 AEA821Hu ELISA Kit for Anti-C Reactive Protein Antibody (Anti-CRP) 96T Cloud-Clone 74750 AEA895Hu ELISA Kit for Anti-Insulin Receptor Antibody (AIRA) 96T Cloud-Clone 74750 AEB028Hu ELISA Kit for Anti-Albumin Antibody (AAA) 96T Cloud-Clone 71250 AEB264Hu ELISA Kit for Insulin Autoantibody (IAA) 96T Cloud-Clone 74750 AEB480Hu ELISA Kit for Anti-Mannose Binding Lectin Antibody (Anti-MBL) 96T Cloud-Clone 88575 AED245Hu ELISA Kit for Anti-Glutamic Acid Decarboxylase Antibodies (Anti-GAD) 96T Cloud-Clone 71250 AEK505Hu ELISA Kit for Anti-Heparin/Platelet Factor 4 Antibodies (Anti-HPF4) 96T Cloud-Clone 71250 CCA005Hu CLIA Kit for Angiotensin II
    [Show full text]